Medical Doctor Program year 2024 Reported 2019–2024 Source: CMS Open Payments, 2026 publication

Alan Jonas

Psychiatry Baltimore, MD Medical Doctor

NPI 1467552521 CMS profile 66724

1314 Bedford Ave, Suite 211, Baltimore, MD 21208

Open in the dashboard

General payments

$19,957

130 records reported · program years 2019–2024

Research payments

$3,881

Paid to them · 2 records reported · program years 2019–2024

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$1,051,153 paid to institutions, not to them · program years 2019–2023

Through program year 2024, Alan Jonas of Baltimore, MD is reported in the CMS Open Payments database as having received $19,957 across 130 general payments and $3,881 in research payments paid to them. Separately, studies naming them as principal investigator received $1,051,153 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 96th percentile of Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

8 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $79 4
2023 General $269 11
2022 General $194 10
2021 General $377 13
2020 General $5,471 8
2020 Research $150 1
2019 General $13,567 84
2019 Research $3,731 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Alan Jonas
  • Psychiatry median
  • Middle half of Psychiatry
  • National median

In program year 2025, general payments to Alan Jonas were reported at $0. Among 14,155 Psychiatry profiles paid that year, the median was $180 and the middle half received between $58 and $685.

Show as a table
Year Alan Jonas Psychiatry median Middle half National median
2019 $13,567 $184 $59–$605 $163
2020 $5,471 $119 $36–$372 $114
2021 $377 $143 $43–$576 $132
2022 $194 $153 $50–$590 $149
2023 $269 $170 $56–$651 $160
2024 $79 $179 $57–$673 $164
2025 $0 $180 $58–$685 $169

Breakdown

Who paid General payments · program years 2019–2024
  1. Janssen Pharmaceuticals, Inc $18,432 39 payments
  2. Corium, Inc. $424 19 payments
  3. Allergan Inc. $199 20 payments
  4. Takeda Pharmaceuticals U.S.A., Inc. $128 10 payments
  5. Amgen Inc. $125 1 payment
  6. Neos Therapeutics, LP $109 11 payments
  7. Otsuka America Pharmaceutical, Inc. $83 5 payments
  8. Bausch Health US, LLC $82 4 payments
  9. Almatica Pharma LLC $74 4 payments
  10. Vanda Pharmaceuticals Inc. $70 4 payments
  11. Other $231 13 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2024
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $14,950 10 payments
  2. Travel and Lodging $2,807 8 payments
  3. Food and Beverage $2,153 111 payments
  4. Education $47 1 payment
Products named General payments · program years 2019–2024
  1. SPRAVATO $18,432 39 payments
  2. Azstarys $424 19 payments
  3. VRAYLAR $199 20 payments
  4. AIMOVIG $125 1 payment
  5. Adzenys XR-ODT $109 11 payments
  6. COTEMPLA XR-ODT $109 11 payments
  7. REXULTI $83 5 payments
  8. WELLBUTRIN $82 4 payments
  9. APLENZIN $82 4 payments
  10. LOREEV XR $74 4 payments
  11. Other $547 33 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2024
  1. Eli Lilly and Company $3,881 2 payments

Prescribing to Medicare patients

Part D · data year 2024 · 17 drugs

Part D claims

329

Median for Psychiatry & Neurology: 100

Drug cost

$20,618

Median for Psychiatry & Neurology: $2,986

Branded share of claims

19.1%

Median for Psychiatry & Neurology: 16.2%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Trintellix Vortioxetine Hydrobromide Brand 11 $15,264
Venlafaxine Hcl Er Venlafaxine Hcl Brand 21 $871
Clonazepam Generic 74 $602
Bupropion Xl Bupropion Hcl Brand 18 $569
Fluoxetine Hcl Generic 21 $544
Clozapine Generic 11 $451
Mirtazapine Generic 13 $437
Risperidone Generic 11 $360
Benztropine Mesylate Generic 11 $295
Escitalopram Oxalate Generic 21 $241

The 10 drugs with the highest cost, of 17 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 10,755 Part D prescribers listed as Psychiatry & Neurology; they describe a distribution and say nothing about conduct.

Payments and prescribing

1 product · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Azstarys
  • Corium, Inc. $79
$79 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

132 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Psychiatry in Maryland

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record